Oncology Nursing News reports on December 08, 2008 that a clinical trial has begun at the Moores Cancer Center at the University of California, San Diego in La Jolla to test the effectiveness of a new vaccine for lung cancer.

The vaccine, called Lucanix (NovaRX Corporation, San Diego, Calif), is made from gene-modified tumor cells. If proved effective, it will not only help a patient’s immune system to fight off cancer, it will also make the cancer shut down its immune system-suppression activities.